<DOC>
	<DOC>NCT01287897</DOC>
	<brief_summary>This is a proof of concept study to determine the efficacy and safety of a monoclonal antibody with three doses versus placebo. Subjects will be randomized to a treatment and the dose will be delivered subcutaneously twice, 4 weeks apart. All subjects will have moderate to severe refractory Crohn's Disease.</brief_summary>
	<brief_title>A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must have failed or are intolerant to anti TNFs hsCRP greater or equal to 5.0 mg/L Ulcerations demonstrated by colonoscopy as defined by SES CD assessment performed within 8 weeks of study entry (screening) and able to retrospectively complete the SESCD or colonoscopy performed during screening Pregnant or breastfeeding women Crohn's Disease with active fistulae or abscess History of diverticulitis or symptomatic diverticulosis Abnormality in hematology or chemistry profiles at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Crohn's Disease Activity Index (CDAI)</keyword>
</DOC>